Our pipeline

We are committed to building a pipeline of products to address a range of neurological diseases

Jennifer, person with Parkinson’s, power puncher

On February 1, 2021, the FDA approved second indication for GOCOVRI® as an adjunctive treatment to levodopa/carbidopa in Parkinson’s disease patients experiencing OFF episodes

To learn more please read our press release.

 

ADS-4101 in development for the treatment of partial onset seizures in patients with epilepsy (program paused)

ADS-4101 is an investigational high-dose, modified release lacosamide capsule, taken once-daily at bedtime. Lacosamide is an anti-epilepsy active ingredient previously approved by the FDA and currently marketed by UCB SA/NV as VIMPAT® (lacosamide).

The ADS-4101 development program is currently paused as we are evaluating the potential value and options for a path forward for this candidate.

Thriving with Parkinson's

 

“People are sometimes told to go home and find a comfortable chair. Well, I decided early on to do the opposite.”

– John, person with Parkinson’s, determined runner and PD fundraiser

Related link